Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01137123 | Improve the Treatment of Thoracic Esophageal Cancer | completed | Phase 3 | 301 | Sun Yat-sen UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 12 | NYU Langone HealthOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04822103 |
| A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer |
| completed |
| — |
| 155 |
| Guangdong Provincial People's HospitalOTHER |
| 1 |
| Mar 18, 2022 |
| clinicaltrials |
| NCT05287880 | Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC | unknown | — | 60 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Mar 18, 2022 | clinicaltrials |
| NCT04390958 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT01868139 | Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)(ICE-CANCER) | terminated | N/A | 1 | University of Maryland, BaltimoreOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT03917966 | The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC | unknown | Phase 2 | 80 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05265962 | Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 85 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Mar 4, 2022 | clinicaltrials |
| NCT00393068 | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | completed | Phase 2 | 62 | SCRI Development Innovations, LLCOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02970539 | Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 2 | Feb 16, 2022 | clinicaltrials |
| NCT02459457 | A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer | completed | Phase 3 | 321 | Fudan UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT04177797 | Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT01077817 | Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352) | completed | — | 684,815 | Organon and CoINDUSTRY | 0 | Feb 3, 2022 | clinicaltrials |
| NCT04390945 | Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer | unknown | Phase 2 | 62 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT01445327 | Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers | terminated | — | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04316689 | First-in-human Study of S-588210 (S-488210+S-488211) | completed | Phase 1 | 10 | ShionogiINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05208775 | A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer | unknown | N/A | 46 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT04615806 | The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy | unknown | N/A | 40 | Fujian Medical University Union HospitalOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05199649 | Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora | unknown | N/A | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05183958 | A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer | unknown | Phase 2 | 118 | Zhejiang Cancer HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05174325 | Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05007145 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma(REVO) | unknown | Phase 2 | 92 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT04286958 | A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC(ESCC) | unknown | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT04520867 | STRENGTH Expansion | withdrawn | — | 0 | University of Colorado, DenverOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05130684 | Neo-NTP-CRT for Locally Advanced ESCC(Neo-NTP-CRT) | unknown | Phase 2 | 43 | National Taiwan University HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04196075 | The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer(AP) | completed | Phase 3 | 30 | Chinese University of Hong KongOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT02749513 | Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients | unknown | Early Phase 1 | 18 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03008980 | WATS3D for the Detection of Esophageal Dysplasia | completed | — | 160 | CDx DiagnosticsINDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04018872 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | recruiting | Phase 2 | 78 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03799380 | DRIHNC - Dehydration Reduction in Head & Neck Cancer | completed | N/A | 41 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05105945 | Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy | not yet recruiting | N/A | 1,164 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04519905 | Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) | recruiting | N/A | 320 | Fudan UniversityOTHER | 1 | Nov 2, 2021 | clinicaltrials |
| NCT05103501 | Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy(SINCERE) | unknown | Phase 2 | 54 | Shanghai Chest HospitalOTHER | 0 | Nov 2, 2021 | clinicaltrials |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | withdrawn | N/A | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 27, 2021 | clinicaltrials |
| NCT05088304 | GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer | completed | — | 205 | Jinling Hospital, ChinaOTHER | 0 | Oct 21, 2021 | clinicaltrials |
| NCT03095209 | Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery | completed | — | 6 | Fox Chase Cancer CenterOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT01806649 | BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy | terminated | Phase 2 | 5 | Prince of Songkla UniversityOTHER | 1 | Oct 11, 2021 | clinicaltrials |
| NCT00591123 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | completed | Phase 2 | 38 | Translational Oncology Research InternationalOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT00381706 | Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | completed | Phase 2 | 245 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT04581005 | Prehabilitation in Esophageal Cancer Care | unknown | N/A | 54 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05049681 | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | unknown | Phase 3 | 234 | Feng WangOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT02857218 | Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 16, 2021 | clinicaltrials |
| NCT04426955 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Mar 31, 2022source: clinicaltrials